Clinical trials: Venous Occlusion
Macular Edema
Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)
This study will assess the safety and efficacy of 700 μg dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in patients with macular edema in a 6 month double-blind period versus sham followed by…
- Trial name
- NCT01660802
- Testing
- 700 μg Dexamethasone
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Allergan
Macular Edema, Retinal Vein Occlusion
Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.
- Trial name
- NCT01618266
- Testing
- dexamethasone intravitreal implant
- Where
- France
- Volunteers
- 375 people
- Sponsor
- Allergan
Macular Edema, Retinal Vein Occlusion
Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®
This study will use retrospective data to evaluate the safety and efficacy of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) in the treatment of macular oedema due to retinal vein occlusion (RVO) in clinical practice.
- Trial name
- NCT02181530
- Testing
- No Intervention
- Where
- Poland
- Volunteers
- 43 people
- Sponsor
- Allergan
Macular Edema, Branch Retinal Vein Occlusion
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at…
- Trial name
- BALATON (NCT04740905)
- Testing
- Faricimab, Aflibercept
- Where
- 150 sites in United States, Argentina and 20 more
- Volunteers
- 553 people
- Sponsor
- Hoffmann-La Roche
Age-Related Macular Degeneration, Geographic Atrophy
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
To conduct a precision study to assess the microperimetry function of the Spectral OCT/SLO. The study will assess variability across measurements taken by three different operator-device configuration across clinical sites…
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT01692938
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch…
- Trial name
- BRAVO (NCT00486018)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 397 people
- Sponsor
- Genentech, Inc.
Venous Thromboses, Venous Disease
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
This study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for…
- Conditions
- Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis
- Trial name
- NCT05409976
- Testing
- GORE® VIAFORT Vascular Stent
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 136 people
- Sponsor
- W.L.Gore & Associates
Branch Retinal Vein Occlusion
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) compared to laser treatment in…
- Trial name
- VIBRANT (NCT01521559)
- Testing
- Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
- Where
- 56 sites in United States, Canada and 1 more
- Volunteers
- 183 people
- Sponsor
- Regeneron Pharmaceuticals
Neovascular Age-related Macular Degeneration, Macular Edema
A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT06176963
- Testing
- SB11 PFS
- Where
- 3 sites in Poland
- Volunteers
- 34 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Macular Edema, Retinal Vein Occlusion
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.
- Trial name
- COBALT (NCT01903720)
- Testing
- dexamethasone implant
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Allergan
Retinal Vein Occlusion, Macular Edema
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.
- Trial name
- NCT01568021
- Testing
- No Intervention
- Where
- 3 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Allergan
Retinal Vein Occlusion, Macular Edema
Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
This study will evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex®) compared to ranibizumab (Lucentis®) in patients with branch retinal vein occlusion (BRVO).
- Trial name
- NCT01427751
- Testing
- dexamethasone intravitreal implant, ranibizumab
- Where
- 6 sites in France, Germany and 4 more
- Volunteers
- 307 people
- Sponsor
- Allergan
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to…
- Trial name
- CRUISE (NCT00485836)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 392 people
- Sponsor
- Genentech, Inc.
Peripheral Arterial Occlusive Disease
GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft
The primary patency of the GORE PROPATEN Vascular Graft is equivalent to or better than disadvantaged autologous vein graft in an infragenicular peripheral bypass application at 12 months.
- Trial name
- PRODIGY (NCT00617279)
- Testing
- GORE PROPATEN Vascular Graft, Disadvantaged Autologous Vein Graft
- Where
- 17 sites in United States
- Volunteers
- 31 people
- Sponsor
- W.L.Gore & Associates
Macular Edema Secondary to Retinal Vein Occlusion
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO). In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked.
- Trial name
- QUASAR (NCT05850520)
- Testing
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Fluorescein
- Where
- 273 sites in United States, Australia and 25 more
- Volunteers
- 892 people
- Sponsor
- Bayer
Retinal Vein Occlusion, Age Related Macular Degeneration
Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion…
- Trial name
- NCT02140411
- Testing
- Ranibizumab Intravitreal injections
- Where
- Chile
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion, Macular Oedema
Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion
The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received…
- Trial name
- NCT01566526
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Belgium
- Volunteers
- 26 people
- Sponsor
- Allergan
Macular Edema
A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)
This study will use retrospective data to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular oedema due to Retinal Vein Occlusion (RVO).
- Trial name
- NCT01445626
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Allergan
Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO
- Trial name
- Camellia (NCT01976312)
- Testing
- Ranibizumab 0.5 mg
- Where
- 34 sites in China, Hong Kong and 5 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Venous Disorder, Venous Outflow Obstruction
VIRTUS: An Evaluation of the Vici™ Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow Obstruction
This is a prospective, multi-center, single arm, non-randomized study to define safety and efficacy of the Veniti Vici™ Venous Stent System in relation to pre-defined Objective Performance goals.
- Conditions
- Chronic Venous Disorder, Venous Outflow Obstruction, Symptomatic Venous Outflow Obstruction of Iliofemoral Vein
- Trial name
- VIRTUS (NCT02112877)
- Testing
- Veniti Vici™ Venous Stent System
- Where
- 24 sites in United States, France and 5 more
- Volunteers
- 200 people
- Sponsor
- Boston Scientific Corporation